Novel Coronavirus (COVID-19)-Associated Guillain–Barre’ Syndrome: Case Report

Mantefardo, Bahru; Gube, Addisu Alemayehu; Awlachew, Ephrem; Sisay, Gizaw

doi:10.2147/imcrj.s305693

Cited by 8 publications

(5 citation statements)

References 9 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight patients died, two of them due to cardiac arrest, two developed multiple organ failure, one due to severe respiratory distress, one was hemodynamically unstable, one developed severe autonomic dysfunction, and the last one developed respiratory failure secondary to GBS [ 25 , 26 , 27 , 28 , 29 , 30 , 31 ].…”

Section: Resultsmentioning

confidence: 99%

“…Our review had some strengths. Firstly, the inclusion of 73 cases report [ 5 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 27 , 29 , 30 , 31 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , ...…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Guillain-Barré Syndrome in the COVID-19 Pandemic

Tawakul

Al-Doboke

Altayyar

et al. 2021

Neurology International

View full text Add to dashboard Cite

There have been several reported cases of severe acute respiratory syndrome (SARS-CoV-2) infection that were associated with an increased incidence of neurological manifestations, including Guillain–Barré syndrome (GBS). This review aims to present information on the reports of GBS associated with coronavirus disease 2019 (COVID-19) infection. Our review is retrospective work examining articles published from the 1 April 2020 to the 8 May 2021 in the English language. We used the diagnostic criteria and classification published by the National Institute of Neurological Disorders and Stroke and Brighton Collaboration. GBS is usually a postinfectious syndrome, but GBS in the COVID-19 pandemic also takes on a para-infectious profile. In the reports, the genetic factor has a role in developing GBS in some patients. In conclusion, the association between COVID-19 and GBS is not very clear. Still, one mechanism is strongly associated with COVID-19 and immune-mediated neurological complications, which is molecular mimicry between SARS-CoV-2 and human autoantigens.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Guillain-Barré Syndrome in the COVID-19 Pandemic

Tawakul

Al-Doboke

Altayyar

et al. 2021

Neurology International

View full text Add to dashboard Cite

show abstract

“…The COVID-19 virus-induced immune dysregulation is reinforced by the documented recent association between immune thrombocytopenic purpura (ITP) and COVID-19 [ 9 ]. Other forms of autoimmune disorders in association with COVID-19 infection, including development of lupus anticoagulants [ 10 ], autoimmune hemolytic anemia [ 11 ] and Guillain-Barre syndrome [ 12 ] are increasingly reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

Acquired Hemophilia A Developed Post COVID-19 Vaccine: An Extremely Rare Complication

et al. 2022

View full text Add to dashboard Cite

“…Vojdani and Kharrazian [ 99 ] discovered that 21 out of 50 human tissue antigens had moderate to high strength responses to SARS-CoV-2 antibody, suggesting an antigenic cross-reaction between the SARS-CoV-2 epitope and various human tissue antigens. This cross-reaction can result in high titers of autoantibodies, inducing Guillain–Barre syndrome [ 100 ], lupus, antiphospholipid syndrome, and ANCA-associated vasculitis [ 98 ]. Franke et al [ 101 ] found that high levels of antibodies were detected in patients’ cerebrospinal fluid.…”

Section: Immunotherapymentioning

confidence: 99%

Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy

Cheng

Zhan

et al. 2022

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The current COVID-19 global pandemic poses immense challenges to global health, largely due to the difficulty to detect infection in the early stages of the disease, as well as the current lack of effective antiviral therapy. Research and understanding of the human immune system can provide important theoretical and technical support for the clinical diagnosis and treatment of COVID-19, the clinical implementations of which include immunoassays and immunotherapy, which play a crucial role in the fight against the pandemic. This review consolidates the current scientific evidence for immunoassay, which includes multiple methods of detecting antigen and antibody against SARS-CoV-2. We compared the characteristics, advantages and disadvantages, and clinical applications of these three detection techniques. In addition to detecting viral infections, knowledge on the body’s immunity against the virus is desirable; thus, the immunotherapy-based neutralizing antibody (nAb) detection methods were discussed. We also gave a brief introduction to the new immunoassay technology such as biosensing. This was followed by an in-depth and extensive review on a variety of immunotherapy methods. It includes convalescent plasma therapy, neutralizing antibody–based treatments targeting different regions of SARS-CoV-2, immunotherapy targeted on the host cell including inhibiting the host cell receptor and cytokine storm, as well as cocktail antibodies, cross-neutralizing antibodies, and immunotherapy based on cross-reactivity between viral epitopes and autoepitopes and autoantibody. Despite the development of various immunological testing methods and antibody therapies, the current global situation of COVID-19 is still tense. We need more efficient detection methods and more reliable antibody therapies. The up-to-date knowledge on therapeutic strategies will likely help clinicians worldwide to protect patients from life-threatening viral infections.

show abstract

Novel Coronavirus (COVID-19)-Associated Guillain–Barre’ Syndrome: Case Report

Cited by 8 publications

References 9 publications

Guillain-Barré Syndrome in the COVID-19 Pandemic

Guillain-Barré Syndrome in the COVID-19 Pandemic

Acquired Hemophilia A Developed Post COVID-19 Vaccine: An Extremely Rare Complication

Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy

Contact Info

Product

Resources

About